Schechter Investment Advisors LLC Increases Stake in Pfizer Inc. (NYSE:PFE)

Schechter Investment Advisors LLC grew its position in shares of Pfizer Inc. (NYSE:PFE) by 108.4% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 17,456 shares of the biopharmaceutical company’s stock after buying an additional 9,079 shares during the quarter. Schechter Investment Advisors LLC’s holdings in Pfizer were worth $442,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of PFE. Brighton Jones LLC increased its holdings in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC increased its holdings in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares in the last quarter. Madison Investment Advisors LLC purchased a new position in shares of Pfizer in the 4th quarter valued at about $5,360,000. Creative Financial Designs Inc. ADV increased its holdings in shares of Pfizer by 4.7% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 44,882 shares of the biopharmaceutical company’s stock valued at $1,191,000 after purchasing an additional 2,023 shares in the last quarter. Finally, Cibc World Markets Corp increased its holdings in shares of Pfizer by 17.3% in the 4th quarter. Cibc World Markets Corp now owns 902,242 shares of the biopharmaceutical company’s stock valued at $23,936,000 after purchasing an additional 133,084 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

PFE opened at $24.63 on Wednesday. The company’s 50 day simple moving average is $23.95 and its 200 day simple moving average is $24.77. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The stock has a market capitalization of $140.00 billion, a PE ratio of 17.84, a P/E/G ratio of 0.92 and a beta of 0.58.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. During the same period last year, the company earned $0.82 earnings per share. The company’s quarterly revenue was down 7.8% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.98%. Pfizer’s payout ratio is 124.64%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on PFE. Morgan Stanley increased their price target on shares of Pfizer from $31.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, April 30th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. TD Cowen dropped their target price on shares of Pfizer from $32.00 to $28.00 and set a “hold” rating for the company in a report on Tuesday, April 22nd. Cantor Fitzgerald assumed coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price for the company. Finally, Redburn Atlantic dropped their target price on shares of Pfizer from $29.00 to $27.00 and set a “neutral” rating for the company in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.